Company intelligence / Profile preview

ATVC

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

AtheroVax (ATVC) was a biotechnology company focused on developing therapeutic vaccines for the treatment and prevention of atherosclerosis and related cardiovascular diseases. The company's primary research centered on targeting Cholesteryl ester transfer protein (CETP) to modulate lipid profiles and reduce the formation of arterial plaques. By utilizing an active immunization approach, AtheroVax aimed to provide a long-lasting alternative to daily oral statins or injectable monoclonal antibodies. Despite promising early-stage research, the company is no longer active in the clinical development space.

Therapeutic areas: Cardiovascular
Modalities: VaccineAntibodyProtein
Industry: Biotech

Beyond the preview

Go deeper on ATVC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATVC.

Explore the full profile